AUSAF (Australis Capital) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Australis Capital 5-Year Yield-on-Cost %?

Australis Capital AUSAF 5-Year Yield-on-Cost % is 0.00 as of Jul. 19, 2026.

Australis Capital's yield on cost for the quarter that ended in Dec. 2021 was 0.00.


The historical rank and industry rank for Australis Capital's 5-Year Yield-on-Cost % or its related term are showing as below:



AUSAF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.29
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Australis Capital  (OTCPK:AUSAF) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Australis Capital 5-Year Yield-on-Cost % Related Terms

AUSAF vs ZTS, CTLT, VTRS: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Australis Capital's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australis Capital 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Australis Capital's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Australis Capital's 5-Year Yield-on-Cost % falls into.


Australis Capital 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Australis Capital is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Australis Capital (AUSAF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 19, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Australis Capital and its competitors.
Is Australis Capital's 5-Year Yield-on-Cost % too high?
Australis Capital's current 5-Year Yield-on-Cost % is 0.00.
How does Australis Capital's 5-Year Yield-on-Cost % compare to ZTS and CTLT?
Australis Capital's 5-Year Yield-on-Cost % of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median 5-Year Yield-on-Cost % is 2.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Australis Capital and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australis Capital's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australis Capital stock overvalued right now?
Australis Capital (AUSAF) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Australis Capital (AUSAF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Australis Capital Business Description

Address 376 E. Warm Springs Road, Suite 190, Las Vegas, NV, USA, 89119
Australis Capital Inc operates as a multi-state operator in the cannabis industry in the US. The company is focused on brands and attractive cannabis licenses in states with favorable economics. AUSA is building an MSO based on a unique and very difficult to imitate strategy. Secure access to low-cost but high-quality biomass enables the company to fuel the expansion of its footprint across the US. The company has a rapidly growing footprint in the U.S. in states, such as California, Nevada, Massachusetts, Missouri, Oklahoma, as well as international operations through its subsidiary ALPS, with projects in Europe, Asia and North America.